Yuying Tan

Boston University — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

40h-index4.5kcitations190works1.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Research and Treatments(64), Virus-based gene therapy research(49), Epigenetics and DNA Methylation(39), Spectroscopy Techniques in Biomedical and Chemical Research(32), Nanoplatforms for cancer theranostics(27)

Publications190 total

NIR-II organic fluorophores integrated with blood–brain barrier-penetrating strategies for brain disease theranostics
Coordination Chemistry Reviews·2025· 1 cited
Demographics, cardiopulmonary comorbidities, laboratory data and length of hospital stay in patients with acute exacerbation of chronic obstructive pulmonary disease at high altitude: A comparative study
Experimental and Therapeutic Medicine·2025Open Access
CDKN3 emerges as a promising diagnostic and prognostic biomarker in hepatocellular carcinoma
Asian Journal of Surgery·2025Open Access
Self-supervised elimination of non-independent noise in hyperspectral imaging
Newton·2025· 5 citedOpen Access
O-074 ASZ1-orchestrated dual epigenetic mechanisms underpinning meiotic fidelity
Human Reproduction·2025Open Access
Label-free nanoscopy of cell metabolism by ultrasensitive reweighted visible stimulated Raman scattering
Nature Methods·2025· 26 citedOpen Access
Self-Supervised Elimination of Non-Independent Noise in Hyperspectral Imaging
arXiv (Cornell University)·2024· 1 citedOpen Access
MafG/MYH9-LCN2 axis promotes liver fibrosis through inhibiting ferroptosis of hepatic stellate cells
Cell Death and Differentiation·2024· 29 citedOpen Access
Supplementary Material and Methods S1 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
2024Open Access
Supplementary Table S2 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
2024Open Access
Supplementary Table S1 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
2024Open Access
Supplementary Figure S4 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
2024Open Access
Supplementary Table S6 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
2024Open Access
Supplementary Table S2 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
2024Open Access
Supplementary Figure S3 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
2024Open Access
Supplementary Table S9 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
2024Open Access
Supplementary Table S3 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
2024Open Access
Supplementary Table S7 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
2024Open Access
Supplementary Figure S6 from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
2024Open Access
Data from Preclinical Evaluation of NTX-301, a Novel DNA Hypomethylating Agent in Ovarian Cancer
2024Open Access
page 1 of 10Next →

Frequent Co-authors

Robert M. Hoffman(32), Qinghong Han(24), Shukuan Li(18), Kentaro Miyake(16), Kentaro Igarashi(16), Kei Kawaguchi(14), Tasuku Kiyuna(13), Ji‐Xin Cheng(12), Michael Bouvet(11), Scott D. Nelson(10), Sarah Dry(10), Fritz C. Eilber(10), Takashi Higuchi(9), Arun S. Singh(9), Tara A. Russell(9), Masuyo Miyake(8), Shree Ram Singh(8), Michiaki Unno(8), Hiromichi Oshiro(7), Norio Yamamoto(7)